Recardio

Jun 29 2020

Interim Analysis of Recardio’s Phase II Clinical Trial to be Presented at the 2020 Congress of the European Society of Cardiology

San Francisco, June 29, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio’s Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29th through September 1st.

May 15 2020

Clinical Trial Outcomes of Recardio’s Dutogliptin Published in the British Journal of Pharmacology

San Francisco, May 15, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial”, the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

Feb 17 2020

Recardio Completes Interim Analysis of Phase 2 in AMI

San Francisco, February 17, 2020 – Recardio Inc., a clinical stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.

Jan 13 2020

Recardio at J.P. Morgan Conference 2020

San Francisco, January 13, 2020 – Recardio Inc., a clinical-stage life science company focusing on therapies for cardiovascular diseases, was participating in the 38^th Annual J.P. Morgan Healthcare Conference in San Francisco.

Dec 13 2019

Closing of Series B Financing Round

San Francisco, December 13th, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the closing of its Series B financing round.